Advertisement

Current Heart Failure Reports

, Volume 10, Issue 4, pp 434–440 | Cite as

Biological and Analytical Variation of Clinical Biomarker Testing: Implications for Biomarker-guided Therapy

  • Alan H. B. WuEmail author
Biomarkers of Heart Failure (WHW Tang, Section Editor)

Abstract

Testing for serum-based biomarkers are essential for diagnosis, risk stratification, and management of patients with cardiovascular disease. All biomarker assays have inherent analytical variability (coefficient of variance CVA), ranging from 5–20 %. There are also variances within a subject over time (CVI) and between subjects (CVG). Variances are determined by experimentation under controlled conditions on healthy subjects. Once measured, the index of individuality (II), reference change value (RCV), and number of samples to establish a homeostatic set point can be calculated. These attributes affect how results of biomarker tests are interpreted in routine clinical practice such as cardiac troponin for acute coronary syndromes, the natriuretic peptides, galectin-3 and sST2 for heart failure, lipids and lipoproteins for primary cardiovascular disease risk, and liver function tests and skeletal muscle biomarkers for detecting complications from statin use.

Keywords

Biological variation Analytical variation Heart failure Acute coronary syndromes Cardiovascular disease risk 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Alan H.B. Wu is supported by grants from BG Medicine, Inc. and Singulex, and has also received compensation from Singulex for lectures given, including service on speakers bureaus, royalties, and reimbursement for travel/accommodations/meeting expenses.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Fraser CG. Biological variation: from principles to practice. Washington, DC: Am Assoc Clin Chem Press; 2001.Google Scholar
  2. 2.
    Apple FS. A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin Chem. 2010;57:1303–6.Google Scholar
  3. 3.
    Wu AHB, Lu A, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I with a high-sensitivity assay: implications for clinical practice. Clin Chem. 2009;55:52–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS. Biological variation of a novel cardiac troponin I assay. Clin Chem. 2011;58:1080–1.CrossRefGoogle Scholar
  5. 5.
    Frankenstein L, Wu AHB, Hallermayer K, Wians Jr FH, Giannitsis E, Katus HA. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem. 2011;58:1068–71.CrossRefGoogle Scholar
  6. 6.
    Apple FS, Murakami MM, Wians FH, Ler R, Kaczmarek JM, Wu AHB. Short-term biological variation of cardiac troponin I measured with three high-sensitivity assays. Clin Chem. 2011;57:C-05.Google Scholar
  7. 7.
    Goldberg J, Iriate B, Prostko J, Frias E, Ravalico T, Hebbar S. Short and long-term biological variability of troponin I determined using the Architect stat high sensitivity troponin I assay. Clin Chem. 2011;57:C-04.Google Scholar
  8. 8.
    Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:1086–90.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Nordenskjold AM, Ahlstrom H, Eggers KM, et al. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem. 2013;59:401–9. In addition to original data, this paper provides a review of the studies published to date on biological variation for cardiac troponin.PubMedCrossRefGoogle Scholar
  11. 11.
    Wu AHB. Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain. Clin Chim Acta. 2009;401:170–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Aldous SJ, Richards AM, Cullen L, Than MP. Early dynamic change inhigh-sensitivity cardiac troponin T in the investigation of acute myocardial infarction. Clin Chem. 2011;57:1154–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MAM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Cnem. 2009;55:930–7.CrossRefGoogle Scholar
  14. 14.
    Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA. 2011;305:2684–93.CrossRefGoogle Scholar
  15. 15.
    •• Mueller M, Biener M, Vafaie M, Doerr S, et al. bsolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndromes and in patients with increased troponin in the absence of acute coronary syndromes. Clin Chem. 2012;58:209–18. Provides evidence that an absolute cutoff concentration for serial change in troponin may be superior to relative change.PubMedCrossRefGoogle Scholar
  16. 16.
    Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172:1211.PubMedCrossRefGoogle Scholar
  17. 17.
    Wu AHB, Smith AC, Mather JF, Duncan B, White CM, Ahlberg A, et al. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Fokkema MR, Hermann Z, Muskiet FAJ, Moecks J. Reference change values for brain natriuretic peptides revisted. Clin Chem. 2006;51:1602–3.CrossRefGoogle Scholar
  19. 19.
    Melzi d’Eril G, Tagnochetti T, Nauti A. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem. 2003;49:1554–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Bruins S, Fokkema MR, Pomer JWP, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and B-type proBNP in patients with stable chronic heart failure. Clin Chem. 2004;50:2052–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim HN, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biological variation in interpretation of results. Am Heart J. 2006;152:828–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Lok DJA, Van Der Meer P, Bruggink PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Shah RV, Januzzi Jr JL. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7:9–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implications on interpretation of test results. Am Heart J. 2013;165:995–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest. 1999;59:491–500.PubMedCrossRefGoogle Scholar
  27. 27.
    Kafonek SD, Derrgy CA, Bachorik PS. Biological variability of lipoproteins and apolipoproteins in patients referred to a lipid clinic. Clin Chem. 1992;38:864–72.PubMedGoogle Scholar
  28. 28.
    Braga F, Panteghini M. Biological variability of C-reactive protein: is the available information reliable. Clin Chim Acta. 2012;413:1179–83.PubMedCrossRefGoogle Scholar
  29. 29.
    Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC scientific statement. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professions from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMedCrossRefGoogle Scholar
  30. 30.
    Fraser CG. Test result variation and the quality of evidence-based guidelines. Clin Chim Acta. 2004;346:19–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Ridker PM, Danielson E, Fonseca FAH, et al. for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Wu AHB, Christenson RH. Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. Clin Biochem. 2013;12:969–78. A review of the merits for high-sensitivity cardiac troponin assays for potential use in primary care.CrossRefGoogle Scholar
  33. 33.
    Wu AHB, Smith A, Wians F. Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta. 2009;399:109–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Laboratory MedicineUniversity of California, San Francisco, San Francisco General HospitalSan FranciscoUSA

Personalised recommendations